ERBB2 and cholangiocarcinoma: Upon further assessment using immunohistochemical staining, fluorescence in situ hybridization and sequencing found that none of the previous cases were those of HER2-overexpression, and therefore it cannot be definitively concluded that lapatinib is ineffective at treating HER2+ CCA.